The names pet owners actually run into online — what the human and rodent research shows, what veterinary evidence exists (often none), and why that gap matters for your dog, cat, or horse.
Notice a theme? A lot of the momentum behind animal-peptide interest is spilling over from human research. If that side of the story is what actually brought you here, PeptideReport.ai is our sister site covering peptide research for people — register there and get The Peptide Bridge audiobook free, a $29.99 value, delivered to your inbox right away.
Visit PeptideReport.ai + get the free book →Every peptide below gets the same four questions: what it is, what's been studied in humans or lab animals, what's actually been studied in dogs, cats, or horses, and what species-specific biology should give you pause. When the honest answer to "what's the veterinary evidence?" is "none found," we say that plainly instead of filling the gap with borrowed human data.
This page names compounds for educational identification only. It does not describe how to obtain, prepare, dose, or administer any of them, and it is not a recommendation to use any peptide in an animal. Every one of these compounds is either unapproved for veterinary use, investigational, or — in the case of "research use only" products sold online — explicitly not manufactured or labeled for use in any living being. Whether any of this research is relevant to your specific pet is a question for a licensed veterinarian, not this website. See our regulatory status page for why that distinction is a legal one, not just a formality.
Two documented pharmacology facts explain a lot of why "it's studied in humans" or "it's studied in rats" tells you very little about a dog, cat, or horse:
Neither of these facts is peptide-specific — they're general veterinary pharmacology. But they're the reason "extrapolated from a human or rat study" is never a substitute for actual veterinary data, and why a licensed vet who knows your pet's breed, species, and health history is the only one positioned to weigh in.
A quick-scan summary before the full entries below. Jump to any row for the complete write-up, including sourcing.
| Peptide | Category | Human/rodent evidence | Veterinary evidence |
|---|---|---|---|
| BPC-157 | Tissue-repair | Extensive rat tendon/GI research; human trial data limited | Rat & dog PK study only (no efficacy data) |
| TB-500 / Thymosin Beta-4 | Tissue-repair | Decades of rodent wound-healing models | None found |
| GHK-Cu | Tissue-repair | In-vitro + rodent skin/wound models | None found |
| KPV | Tissue-repair | Mouse colitis model | None found |
| Thymosin Alpha-1 | Immune-modulating | Approved abroad (as thymalfasin) for hepatitis; not FDA-approved in the U.S. | None found |
| CJC-1295 | Growth-hormone axis | Human adult + GHRH-knockout mouse studies | None found |
| Ipamorelin | Growth-hormone axis | Rat pituitary cell & pig pharmacology studies | None found |
| Epitalon | Longevity/neuro | Human cohort + multi-species data, largely single research group | None found |
| Semax | Longevity/neuro | Unverified in this research pass — flagged as an evidence gap | None found |
| Selank | Longevity/neuro | Unverified in this research pass — flagged as an evidence gap | None found |
| MOTS-c | Metabolic | Rodent research, cited mostly via secondary sources | None found |
| AOD-9604 | Metabolic | Preclinical + reported human Phase II; not FDA-approved | None found |
What it is: A synthetic 15-amino-acid peptide based on a partial sequence identified in human gastric juice. In laboratory research it's studied for effects on angiogenesis (new blood vessel growth), tendon and muscle repair signaling, and gastrointestinal lining integrity.
Human & rodent evidence: The bulk of the published research is preclinical rat work, including a widely cited study in the Journal of Applied Physiology showing effects on tendon fibroblast outgrowth, survival, and migration. More recent narrative and systematic reviews (2025, in Current Reviews in Musculoskeletal Medicine and a sports-medicine systematic review) describe a biologically plausible mechanism but are consistent in flagging that controlled human clinical trial data remains very limited, and that BPC-157 is not an FDA-approved drug for any human indication.
Veterinary evidence: This is one of the few peptides on this list with an actual peer-reviewed animal pharmacokinetics dataset that includes dogs. A 2022 study in Frontiers in Pharmacology measured BPC-157's absorption, distribution, metabolism, and excretion in Sprague-Dawley rats and beagle dogs, using both intravenous and intramuscular routes. It found an elimination half-life under 30 minutes in both species — but absolute bioavailability after intramuscular injection differed substantially between rats (roughly 14–19%) and dogs (roughly 45–51%). That's a real, measured cross-species difference in the same study, which is exactly why extrapolating a dose or effect from one species to another isn't reliable. Importantly, this was a drug-behavior (pharmacokinetics) study, not a clinical efficacy or safety trial — it did not test whether BPC-157 treats any condition in dogs.
Species-specific caveats: No feline or equine pharmacokinetic data were located. Given that rats and dogs already showed meaningfully different absorption in the one available study, there is no basis to assume cats or horses would behave like either.
What it is: "TB-500" is an informal name associated with thymosin beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation and cell migration, studied in the context of tissue repair.
Human & rodent evidence: Decades of rodent and other animal-model research (summarized in review literature such as "Animal studies with thymosin beta4, a multifunctional tissue repair and regeneration peptide") cover wound healing, cardiac tissue, and corneal repair models. A 2026 peer-reviewed rat study directly compared BPC-157 and TB-500 in Achilles tendon healing using histopathology and biomechanical testing.
Veterinary evidence: No peer-reviewed veterinary clinical trials in dogs, cats, or horses were found in this research. TB-500 comes up constantly in equine and canine sports-injury marketing material online, but none of that material is peer-reviewed veterinary science — it's product marketing, and should be read as such.
Species-specific caveats: None verified; this is an evidence gap, not a green light.
What it is: A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine), studied for roles in collagen and elastin synthesis, extracellular matrix remodeling, and antioxidant signaling — most familiar from topical cosmetic skincare formulations.
Human & rodent evidence: A 2025 review ("Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration") describes proposed mechanisms including copper chelation that stimulates matrix protein synthesis, suppression of inflammatory NF-κB/p38 signaling, and antioxidant activity via superoxide dismutase. The evidence base is strongest in vitro (human dermal fibroblast cultures) and in rodent wound models (mice and rats, including infected-wound and acute-injury models); the same review specifically notes a "lack of clinical trial data" in humans as a limitation.
Veterinary evidence: None found in this search.
Species-specific caveats: Nearly all the in vivo evidence involves topical application in rodent skin models — that's a different exposure route and species than any systemic veterinary use, so it doesn't transfer directly.
What it is: A tripeptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH), studied for local anti-inflammatory signaling, particularly in gut tissue.
Human & rodent evidence: A peer-reviewed study, "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease" (indexed on PubMed), found anti-inflammatory activity in mouse colitis models. That is mouse research — it is not a human clinical trial.
Veterinary evidence: No dog, cat, or horse studies were located.
Species-specific caveats: Canine and feline inflammatory bowel disease are real, well-documented clinical diagnoses, which is likely why KPV comes up in pet-owner searches — but nothing in the current published literature connects KPV specifically to either species. That's a research interest, not an established or studied veterinary use.
What it is: A 28-amino-acid peptide derived from the thymus gland, studied for immune-modulating properties.
Human & rodent evidence: As the synthetic drug thymalfasin (brand name Zadaxin), it has been studied clinically and is approved in dozens of countries outside the United States for chronic hepatitis B and C and as adjunctive immune therapy in various conditions, according to a comprehensive literature review published via the World Journal of Gastroenterology's affiliated journal network. It does not hold general FDA marketing approval in the United States.
Veterinary evidence: No peer-reviewed veterinary clinical trial was located in this search. Thymosin alpha-1 surfaces often in pet-owner discussions of feline immune support, and anecdotally in connection with historical feline infectious peritonitis (FIP) management from before FDA-supported antiviral options existed — but no peer-reviewed veterinary study substantiating that specific use could be confirmed here. That's an honest evidence gap, not a confirmation either way.
Species-specific caveats: Given cats' documented differences in drug clearance (see the glucuronidation note above), an immune-modulating peptide studied in human liver disease would need its own dedicated feline data before it means anything clinically for a cat — promising human research doesn't transfer automatically.
What it is: A synthetic analog of growth hormone-releasing hormone (GHRH), studied for its ability to increase growth hormone and IGF-1 secretion.
Human & rodent evidence: A 2006 study in the Journal of Clinical Endocrinology & Metabolism documented sustained growth hormone and IGF-1 elevation in healthy human adults after CJC-1295 administration. A companion study published the same year in the American Journal of Physiology-Endocrinology and Metabolism examined it in GHRH-knockout mice.
Veterinary evidence: None found.
Species-specific caveats: Growth hormone axis physiology and growth-plate timing vary significantly by species and, in dogs, dramatically by breed size — there is no published basis for extrapolating human GH-secretagogue research to companion animals.
What it is: A pentapeptide growth hormone secretagogue, selective for the ghrelin/GH secretagogue receptor.
Human & rodent evidence: The foundational 1998 study, "Ipamorelin, the first selective growth hormone secretagogue" (European Journal of Endocrinology, indexed on PubMed), tested it in rat pituitary cells, anesthetized rats, and conscious pigs. It found ipamorelin stimulated GH release without significantly raising ACTH or cortisol, distinguishing it from earlier, less-selective GH secretagogues.
Veterinary evidence: The original selectivity research used pigs as a laboratory pharmacology model — that is not the same as a companion-animal clinical trial. No dog, cat, or horse studies were found.
Species-specific caveats: Receptor-selectivity data in a livestock research model doesn't establish safety or efficacy in dogs, cats, or horses.
What it is: A synthetic tetrapeptide modeled on a bovine pineal gland extract, studied primarily by a single Russian research institute for telomerase-activation and aging-related hypotheses.
Human & rodent evidence: Research spans cell cultures (human fibroblasts, lymphocytes), several animal species (mice, rats, chickens, monkeys), and human cohort studies, largely from the St. Petersburg Institute of Bioregulation and Gerontology. Reported mortality-reduction findings come from human prospective cohort studies, but independent replication outside that research group appears limited based on available summaries.
Veterinary evidence: None found for any companion-animal species.
Species-specific caveats: None specifically verified — but it's worth noting that aging biology varies enormously even within dogs (large-breed dogs age on a very different trajectory than small-breed dogs), making cross-species extrapolation especially uncertain here.
What it is: A synthetic heptapeptide derived from a fragment of ACTH, developed in Russia and studied as a nootropic/neuroprotective compound.
Human & rodent evidence: Widely referenced in secondary and commercial sources; this research pass was not able to independently confirm a specific peer-reviewed, English-language clinical trial through the sources available to us. Most retrievable material online is peptide-vendor marketing content rather than indexed biomedical literature. We are flagging this honestly as an unverified area rather than asserting evidence that couldn't be confirmed.
Veterinary evidence: None found.
Species-specific caveats: Not established.
What it is: A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied as an anxiolytic.
Human & rodent evidence: Same limitation as Semax above — widely discussed in secondary and commercial sources, but this research pass could not independently confirm specific peer-reviewed clinical data through the sources available. Flagged as an evidence gap rather than a claim.
Veterinary evidence: None found.
Species-specific caveats: Not established.
What it is: A short peptide encoded within mitochondrial DNA, described in the research literature as a "mitochondrial-derived peptide" studied for roles in metabolic regulation and exercise physiology.
Human & rodent evidence: Originating rodent research on MOTS-c's metabolic effects is widely cited in secondary and commercial peptide literature. This research pass's available sources were predominantly vendor summaries rather than the primary indexed paper, so we are not citing specific trial details we could not independently confirm here.
Veterinary evidence: None found.
Species-specific caveats: Not established.
What it is: A synthetic fragment (amino acids 176–191) of human growth hormone, studied specifically for a fat-metabolizing (lipolytic) effect without the growth-promoting effects of full-length growth hormone.
Human & rodent evidence: Developed and studied by Australian researchers as an anti-obesity drug candidate, with published preclinical metabolic studies and reported human Phase II trials. This research pass could not independently confirm the specific efficacy outcome data from a primary source in the time available, and AOD-9604 has not reached FDA approval as an obesity treatment for humans.
Veterinary evidence: None found.
Species-specific caveats: Not established. Canine and feline obesity are real, common conditions — but that's exactly the kind of overlap that invites unsupported extrapolation, which the evidence here doesn't support.
Read across this whole list and a pattern emerges: rodent and sometimes human evidence exists for a plausible biological mechanism, and veterinary evidence — the kind that would actually tell you whether something is safe or effective in a dog, cat, or horse — is either extremely thin or entirely absent. The one partial exception, BPC-157's canine pharmacokinetics study, measured how the compound moves through a dog's body, not whether it helps any condition, and it found real differences from rats in the process.
That gap is the whole reason this site exists to explain the research landscape rather than to recommend using any of these compounds. If something here is relevant to a condition your pet has, the next step is a conversation with a licensed veterinarian — see Talking to Your Vet for how to bring it up productively.
Understanding what's been studied is only half the picture. See how AMDUCA, VCPR requirements, and FDA compounding guidance determine what a veterinarian can actually prescribe.
Read the Regulatory Status PageFree bonus: register on PeptideReport.ai today and The Peptide Bridge audiobook — a $29.99 value — is yours free, delivered to your inbox right away.